|
A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients Clinical research trials and A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients. A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients clinical trial. Participants frequently obtain the most expert healthcare available for their A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients  A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients
A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): Abbott Laboratories ,
Synopsis: The purpose of this study is to determine how many HIV-infected patients continue taking ritonavir/indinavir combination after having taken indinavir three times a day as part of their anti-HIV drug therapy. This study also examines the safety and effectiveness of the ritonavir/indinavir combination.
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 12 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV infection. - CD4 cell count greater than 100 cells/microliter. - HIV RNA levels greater than 400 copies/microliter using the Roche Ultrasensitive assay. - No acute illness. - Consent of parent or guardian if less than legal age. - No prior enrollment in this study. - All entry criteria for this study met within 15 days prior to enrollment. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: Any condition that in the opinion of the investigator may obscure proper observation of the safety or activity of the treatment regimens used in this study. Concurrent Medication: Excluded: - Concurrent non-nucleoside reverse transcriptase inhibitors as part of the antiretroviral regimen. - Any of the following medications with ritonavir: - midazolam, clorazepate, diazepam, estazolam, flurazepam, triazolam, zolpidem, quinidine, amiodarone, encainide, flecainide, propafenone, bepridil, terfenadine, astemizole, cisapride, bupropion, clozapine, rifabutin, meperidine, propoxyphene, piroxicam, pimozide, dihydroergotamine, and ergotamine. - Any of the following medications with indinavir: - terfenadine, astemizole, cisapride, triazolam, midazolam. No requirement for rifampin or ketoconazole. - Any concurrent treatment with other protease inhibitors. - Other concurrent medication (including over-the-counter medicine or alcohol) without the knowledge and permission of the primary investigator. Patients with the following prior conditions are excluded: - History of significant drug hypersensitivity. - Psychiatric illness that precludes compliance with the protocol. - Receipt of investigational drug within 30 days prior to administration of study drug. - History of acute or chronic pancreatitis. - Anticipation of poor patient compliance with protocol. Prior Medication: Excluded: Prior treatment with ritonavir. Risk Behavior: Excluded: History of active substance abuse (i.e., recreational drugs or alcohol). Included: Indinavir 800 mg three times a day plus unspecified nucleosides for at least 3 months.
Total Enrollment:
Location and Contact Information:
Stephen Hauptman
Philadelphia, Pennsylvania, 19107
United States
Tower Infectious Diseases
Los Angeles, California, 90048
United States
Goodgame Med Ctr / Central Florida Research Initiati
Maitland, Florida, 32751
United States
AIDS Healthcare Foundation
Los Angeles, California, 90027
United States
Urgent Care Ctr / North Broward Hosp District
Ft. Lauderdale, Florida, 33316
United States
Mount Sinai Med Ctr
New York City, New York, 10029
United States
Additional Information:
Study ID Numbers: 245E; M98-823
Study Start Date:
Record last reviewed: April 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002223
Other Hiv Infections Studies:
1. Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
2. A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
3. A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
4. A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
5. A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success with Fluconazole
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients
|
|
|
|
|
|
|
|
